Beam Therapeutics Inc (BEAM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has a cash flow conversion efficiency ratio of -0.110x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-128.51 Million) by net assets ($1.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Beam Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Beam Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beam Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beam Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Companhia Energética de Minas Gerais - CEMIG
SA:CMIG3
|
0.038x |
|
Flat Glass Group Co. Ltd
SHG:601865
|
0.039x |
|
Gulfport Energy Operating Corp
NYSE:GPOR
|
0.162x |
|
Highwealth Construction Corp
TW:2542
|
-0.019x |
|
SL Green Realty Corp
NYSE:SLG
|
0.019x |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
-0.041x |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.145x |
|
Jubilant Foodworks Limited
NSE:JUBLFOOD
|
0.403x |
Annual Cash Flow Conversion Efficiency for Beam Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Beam Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Beam Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.24 Billion | $-345.10 Million | -0.279x | +41.13% |
| 2024-12-31 | $733.54 Million | $-347.25 Million | -0.473x | -211.37% |
| 2023-12-31 | $981.33 Million | $-149.19 Million | -0.152x | -595.02% |
| 2022-12-31 | $733.47 Million | $22.53 Million | 0.031x | +138.32% |
| 2021-12-31 | $826.74 Million | $-66.27 Million | -0.080x | +79.44% |
| 2020-12-31 | $245.56 Million | $-95.74 Million | -0.390x | +45.34% |
| 2019-12-31 | $100.94 Million | $-72.00 Million | -0.713x | -370.99% |
| 2018-12-31 | $134.03 Million | $-20.30 Million | -0.151x | -123.40% |
| 2017-12-31 | $-4.18 Million | $-2.71 Million | 0.647x | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more